- Home
- XERS vs NXJ Comparison
XERS vs NXJ Comparison
Compare XERS & NXJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- NXJ
- Stock Information
- Founded
- XERS 2005
- NXJ 1999
- Country
- XERS United States
- NXJ United States
- Employees
- XERS N/A
- NXJ N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- NXJ Finance/Investors Services
- Sector
- XERS Health Care
- NXJ Finance
- Exchange
- XERS Nasdaq
- NXJ Nasdaq
- Market Cap
- XERS 526.3M
- NXJ 508.0M
- IPO Year
- XERS 2018
- NXJ N/A
- Fundamental
- Price
- XERS $4.24
- NXJ $12.02
- Analyst Decision
- XERS Strong Buy
- NXJ
- Analyst Count
- XERS 4
- NXJ 0
- Target Price
- XERS $5.75
- NXJ N/A
- AVG Volume (30 Days)
- XERS 2.4M
- NXJ 74.9K
- Earning Date
- XERS 03-06-2025
- NXJ 01-01-0001
- Dividend Yield
- XERS N/A
- NXJ 3.27%
- EPS Growth
- XERS N/A
- NXJ N/A
- EPS
- XERS N/A
- NXJ N/A
- Revenue
- XERS $203,070,000.00
- NXJ N/A
- Revenue This Year
- XERS $20.47
- NXJ N/A
- Revenue Next Year
- XERS $19.35
- NXJ N/A
- P/E Ratio
- XERS N/A
- NXJ N/A
- Revenue Growth
- XERS 23.89
- NXJ N/A
- 52 Week Low
- XERS $1.69
- NXJ $10.06
- 52 Week High
- XERS $4.50
- NXJ $12.24
- Technical
- Relative Strength Index (RSI)
- XERS 70.54
- NXJ 38.68
- Support Level
- XERS $3.59
- NXJ $12.21
- Resistance Level
- XERS $4.50
- NXJ $12.24
- Average True Range (ATR)
- XERS 0.25
- NXJ 0.09
- MACD
- XERS 0.03
- NXJ -0.01
- Stochastic Oscillator
- XERS 72.34
- NXJ 2.94
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About NXJ Nuveen New Jersey Qualified Municipal Fund
Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.